骨髓增生异常综合征与继发性急性髓系白血病中的TP53突变赋予免疫抑制表型
本研究刻画了TP53突变型与野生型骨髓增生异常综合征(MDS)或继发性急性髓系白血病(sAML)患者恶性克隆的免疫特征及免疫微环境改变。TP53突变患者造血干细胞PDL1表达显著升高,伴随MYC上调及其负调控因子miR-34a显著下调,骨髓浸润OX40+细胞毒性T细胞和辅助性T细胞减少,ICOS+和4-1BB+自然杀伤细胞减少,免疫抑制性调节性T细胞(Tregs)(即ICOShigh/PD-1-)及髓源性抑制细胞(PD-1low)扩增。骨髓浸润ICOShigh/PD-1- Treg细胞比例较高是全生存期高度显著的独立预测因素。作者结论认为TP53突变型MDS和sAML微环境呈免疫豁免、逃逸表型,可能是预后不良的主要驱动因素,并认为免疫调节治疗策略可能使该分子定义亚群获益。
要点
- TP53突变MDS/sAML患者造血干细胞PDL1表达显著升高,伴MYC上调及miR-34a显著下调。
- TP53突变患者骨髓浸润OX40+细胞毒性T细胞和辅助T细胞显著减少。
- TP53突变患者ICOS+和4-1BB+自然杀伤细胞减少,ICOShigh/PD-1- Treg及PD-1low髓源性抑制细胞扩增。
核心结论
- TP53突变型MDS和sAML微环境呈免疫豁免、逃逸表型,可能是预后不良的主要驱动因素。
- 作者认为免疫调节治疗策略可能使该分子定义亚群获益。
研究设计与样本
- 研究刻画了TP53突变型与野生型MDS或sAML患者恶性克隆的免疫特征及免疫微环境改变。
主要发现
- TP53突变患者造血干细胞PDL1表达显著升高,伴MYC上调及miR-34a显著下调。
- TP53突变患者骨髓浸润OX40+细胞毒性T细胞和辅助T细胞数量显著减少。
- TP53突变患者ICOS+和4-1BB+自然杀伤细胞减少。
- TP53突变患者ICOShigh/PD-1- Treg及PD-1low髓源性抑制细胞扩增。
- 骨髓浸润ICOShigh/PD-1- Treg比例较高是全生存期高度显著的独立预测因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Somatic gene mutations are key determinants of outcome in patients with myelodysplastic syndromes (MDS) and secondary AML (sAML). In particular, patients with TP53 mutations represent a distinct molecular cohort with uniformly poor prognosis. The precise pathogenetic mechanisms underlying these inferior outcomes have not been delineated. In this study, we characterized the immunological features of the malignant clone and alterations in the immune microenvironment in patients with TP53-mutant and wild-type MDS or sAML. Notably, PDL1 expression is significantly increased in hematopoietic stem cells of patients with TP53 mutations, which is associated with MYC upregulation and marked downregulation of MYC's negative regulator miR-34a, a p53 transcription target. Notably, patients with TP53 mutations display significantly reduced numbers of bone marrow-infiltrating OX40+ cytotoxic T cells and helper T cells, as well as decreased ICOS+ and 4-1BB+ natural killer cells. Further, highly immunosuppressive regulatory T cells (Tregs) (ie, ICOShigh/PD-1-) and myeloid-derived suppressor cells (PD-1low) are expanded in cases with TP53 mutations. Finally, a higher proportion of bone marrow-infiltrating ICOShigh/PD-1- Treg cells is a highly significant independent predictor of overall survival. We conclude that the microenvironment of TP53 mutant MDS and sAML has an immune-privileged, evasive phenotype that may be a primary driver of poor outcomes and submit that immunomodulatory therapeutic strategies may offer a benefit for this molecularly defined subpopulation.
引用
- Sallman DA, McLemore AF, Aldrich AL, et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020. PMID: 32730593. doi:10.1182/blood.2020006158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。